Predictors of Progression in Barrett’s Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry

Rajesh Krishnamoorthi, Jason T. Lewis, Murli Krishna, Nicholas J. Crews, Michele L. Johnson, Ross A. Dierkhising, Brenda F. Ginos, Kenneth Ke Ning Wang, Herbert C. Wolfsen, David E. Fleischer, Francisco C Ramirez, Navtej Singh Buttar, David A Katzka, Prasad G Iyer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives:Low-grade dysplasia (LGD) is a risk factor for progression in Barrett’s esophagus (BE). Progression estimates however vary and predictors of progression are not well established. We aimed to assess predictors of progression in a multicenter BE-LGD cohort.Methods:All subjects with LGD (diagnosed by a GI pathologist) in a prospective BE registry were identified. Progression was defined development of HGD/EAC more than 12 months after index date of LGD diagnosis. Clinical, endoscopic factors and impact of histologic review by an independent panel of two GI pathologists were assessed as predictors of progression. Cox proportional hazard models were used to assess their association with risk of progression.Results:244 BE-LGD subjects met inclusion criteria. Their mean age was 63.2 years. 205 (84%) were males. The median follow up was 4.8 years. Fifty six patients were diagnosed with HGD/EAC in less than 12 months, while 14 progressed to HGD/EAC after 12 months, with an overall annual risk of progression of 1.2%. 29% of LGD subjects were downgraded to non-dysplastic and the remaining re-confirmed as LGD or indefinite dysplasia. The risk of progression in the reconfirmed LGD group was eight fold higher (hazards ratio: 7.6, 95% CI: 1.5–139.4) in a propensity score stratified model.Conclusions:In this large BE-LGD cohort, progression risk increased substantially when an additional panel of two expert GI pathologists re-confirmed a LGD diagnosis. These BE subjects may be candidates for endoscopic therapy. LGD was a marker of prevalent HGD/EAC in 18% of patients.Am J Gastroenterol advance online publication, 4 April 2017; doi:10.1038/ajg.2017.84.

Original languageEnglish (US)
JournalAmerican Journal of Gastroenterology
DOIs
StateAccepted/In press - Apr 4 2017

Fingerprint

Barrett Esophagus
Registries
Propensity Score
Proportional Hazards Models
Publications
Pathologists

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Predictors of Progression in Barrett’s Esophagus with Low-Grade Dysplasia : Results from a Multicenter Prospective BE Registry. / Krishnamoorthi, Rajesh; Lewis, Jason T.; Krishna, Murli; Crews, Nicholas J.; Johnson, Michele L.; Dierkhising, Ross A.; Ginos, Brenda F.; Wang, Kenneth Ke Ning; Wolfsen, Herbert C.; Fleischer, David E.; Ramirez, Francisco C; Buttar, Navtej Singh; Katzka, David A; Iyer, Prasad G.

In: American Journal of Gastroenterology, 04.04.2017.

Research output: Contribution to journalArticle

Krishnamoorthi, Rajesh ; Lewis, Jason T. ; Krishna, Murli ; Crews, Nicholas J. ; Johnson, Michele L. ; Dierkhising, Ross A. ; Ginos, Brenda F. ; Wang, Kenneth Ke Ning ; Wolfsen, Herbert C. ; Fleischer, David E. ; Ramirez, Francisco C ; Buttar, Navtej Singh ; Katzka, David A ; Iyer, Prasad G. / Predictors of Progression in Barrett’s Esophagus with Low-Grade Dysplasia : Results from a Multicenter Prospective BE Registry. In: American Journal of Gastroenterology. 2017.
@article{eb1d9fb91b2a45eca2b4268403078021,
title = "Predictors of Progression in Barrett’s Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry",
abstract = "Objectives:Low-grade dysplasia (LGD) is a risk factor for progression in Barrett’s esophagus (BE). Progression estimates however vary and predictors of progression are not well established. We aimed to assess predictors of progression in a multicenter BE-LGD cohort.Methods:All subjects with LGD (diagnosed by a GI pathologist) in a prospective BE registry were identified. Progression was defined development of HGD/EAC more than 12 months after index date of LGD diagnosis. Clinical, endoscopic factors and impact of histologic review by an independent panel of two GI pathologists were assessed as predictors of progression. Cox proportional hazard models were used to assess their association with risk of progression.Results:244 BE-LGD subjects met inclusion criteria. Their mean age was 63.2 years. 205 (84{\%}) were males. The median follow up was 4.8 years. Fifty six patients were diagnosed with HGD/EAC in less than 12 months, while 14 progressed to HGD/EAC after 12 months, with an overall annual risk of progression of 1.2{\%}. 29{\%} of LGD subjects were downgraded to non-dysplastic and the remaining re-confirmed as LGD or indefinite dysplasia. The risk of progression in the reconfirmed LGD group was eight fold higher (hazards ratio: 7.6, 95{\%} CI: 1.5–139.4) in a propensity score stratified model.Conclusions:In this large BE-LGD cohort, progression risk increased substantially when an additional panel of two expert GI pathologists re-confirmed a LGD diagnosis. These BE subjects may be candidates for endoscopic therapy. LGD was a marker of prevalent HGD/EAC in 18{\%} of patients.Am J Gastroenterol advance online publication, 4 April 2017; doi:10.1038/ajg.2017.84.",
author = "Rajesh Krishnamoorthi and Lewis, {Jason T.} and Murli Krishna and Crews, {Nicholas J.} and Johnson, {Michele L.} and Dierkhising, {Ross A.} and Ginos, {Brenda F.} and Wang, {Kenneth Ke Ning} and Wolfsen, {Herbert C.} and Fleischer, {David E.} and Ramirez, {Francisco C} and Buttar, {Navtej Singh} and Katzka, {David A} and Iyer, {Prasad G}",
year = "2017",
month = "4",
day = "4",
doi = "10.1038/ajg.2017.84",
language = "English (US)",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Predictors of Progression in Barrett’s Esophagus with Low-Grade Dysplasia

T2 - Results from a Multicenter Prospective BE Registry

AU - Krishnamoorthi, Rajesh

AU - Lewis, Jason T.

AU - Krishna, Murli

AU - Crews, Nicholas J.

AU - Johnson, Michele L.

AU - Dierkhising, Ross A.

AU - Ginos, Brenda F.

AU - Wang, Kenneth Ke Ning

AU - Wolfsen, Herbert C.

AU - Fleischer, David E.

AU - Ramirez, Francisco C

AU - Buttar, Navtej Singh

AU - Katzka, David A

AU - Iyer, Prasad G

PY - 2017/4/4

Y1 - 2017/4/4

N2 - Objectives:Low-grade dysplasia (LGD) is a risk factor for progression in Barrett’s esophagus (BE). Progression estimates however vary and predictors of progression are not well established. We aimed to assess predictors of progression in a multicenter BE-LGD cohort.Methods:All subjects with LGD (diagnosed by a GI pathologist) in a prospective BE registry were identified. Progression was defined development of HGD/EAC more than 12 months after index date of LGD diagnosis. Clinical, endoscopic factors and impact of histologic review by an independent panel of two GI pathologists were assessed as predictors of progression. Cox proportional hazard models were used to assess their association with risk of progression.Results:244 BE-LGD subjects met inclusion criteria. Their mean age was 63.2 years. 205 (84%) were males. The median follow up was 4.8 years. Fifty six patients were diagnosed with HGD/EAC in less than 12 months, while 14 progressed to HGD/EAC after 12 months, with an overall annual risk of progression of 1.2%. 29% of LGD subjects were downgraded to non-dysplastic and the remaining re-confirmed as LGD or indefinite dysplasia. The risk of progression in the reconfirmed LGD group was eight fold higher (hazards ratio: 7.6, 95% CI: 1.5–139.4) in a propensity score stratified model.Conclusions:In this large BE-LGD cohort, progression risk increased substantially when an additional panel of two expert GI pathologists re-confirmed a LGD diagnosis. These BE subjects may be candidates for endoscopic therapy. LGD was a marker of prevalent HGD/EAC in 18% of patients.Am J Gastroenterol advance online publication, 4 April 2017; doi:10.1038/ajg.2017.84.

AB - Objectives:Low-grade dysplasia (LGD) is a risk factor for progression in Barrett’s esophagus (BE). Progression estimates however vary and predictors of progression are not well established. We aimed to assess predictors of progression in a multicenter BE-LGD cohort.Methods:All subjects with LGD (diagnosed by a GI pathologist) in a prospective BE registry were identified. Progression was defined development of HGD/EAC more than 12 months after index date of LGD diagnosis. Clinical, endoscopic factors and impact of histologic review by an independent panel of two GI pathologists were assessed as predictors of progression. Cox proportional hazard models were used to assess their association with risk of progression.Results:244 BE-LGD subjects met inclusion criteria. Their mean age was 63.2 years. 205 (84%) were males. The median follow up was 4.8 years. Fifty six patients were diagnosed with HGD/EAC in less than 12 months, while 14 progressed to HGD/EAC after 12 months, with an overall annual risk of progression of 1.2%. 29% of LGD subjects were downgraded to non-dysplastic and the remaining re-confirmed as LGD or indefinite dysplasia. The risk of progression in the reconfirmed LGD group was eight fold higher (hazards ratio: 7.6, 95% CI: 1.5–139.4) in a propensity score stratified model.Conclusions:In this large BE-LGD cohort, progression risk increased substantially when an additional panel of two expert GI pathologists re-confirmed a LGD diagnosis. These BE subjects may be candidates for endoscopic therapy. LGD was a marker of prevalent HGD/EAC in 18% of patients.Am J Gastroenterol advance online publication, 4 April 2017; doi:10.1038/ajg.2017.84.

UR - http://www.scopus.com/inward/record.url?scp=85017104764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017104764&partnerID=8YFLogxK

U2 - 10.1038/ajg.2017.84

DO - 10.1038/ajg.2017.84

M3 - Article

C2 - 28374813

AN - SCOPUS:85017104764

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

ER -